Viral loads of Delta-variant SARS-CoV-2 breakthrough infections after vaccination and booster with BNT162b2.
Journal
Nature medicine
ISSN: 1546-170X
Titre abrégé: Nat Med
Pays: United States
ID NLM: 9502015
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
received:
27
08
2021
accepted:
08
10
2021
pubmed:
4
11
2021
medline:
6
1
2022
entrez:
3
11
2021
Statut:
ppublish
Résumé
The effectiveness of the coronavirus disease 2019 (COVID-19) BNT162b2 vaccine in preventing disease and reducing viral loads of breakthrough infections (BTIs) has been decreasing, concomitantly with the rise of the Delta variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, it is unclear whether the observed decreased effectiveness of the vaccine in reducing viral loads is inherent to the Delta variant or is dependent on time from immunization. By analyzing viral loads of over 16,000 infections during the current, Delta-variant-dominated pandemic wave in Israel, we found that BTIs in recently fully vaccinated individuals have lower viral loads than infections in unvaccinated individuals. However, this effect starts to decline 2 months after vaccination and ultimately vanishes 6 months or longer after vaccination. Notably, we found that the effect of BNT162b2 on reducing BTI viral loads is restored after a booster dose. These results suggest that BNT162b2 might decrease the infectiousness of BTIs even with the Delta variant, and that, although this protective effect declines with time, it can be restored, at least temporarily, with a third, booster, vaccine dose.
Identifiants
pubmed: 34728830
doi: 10.1038/s41591-021-01575-4
pii: 10.1038/s41591-021-01575-4
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
COVID-19 Vaccines
0
BNT162 Vaccine
N38TVC63NU
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2108-2110Subventions
Organisme : Israel Science Foundation (ISF)
ID : 3633/19
Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Nature America, Inc.
Références
Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603–2615 (2020).
doi: 10.1056/NEJMoa2034577
Dagan, N. et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N. Engl. J. Med. 384, 1412–1423 (2021).
doi: 10.1056/NEJMoa2101765
Chodick, G. et al. Assessment of effectiveness of 1 dose of BNT162b2 vaccine for SARS-CoV-2 infection 13 to 24 days after immunization. JAMA Netw. Open 4, e2115985 (2021).
doi: 10.1001/jamanetworkopen.2021.15985
Levine-Tiefenbrun, M. et al. Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine. Nat. Med. 27, 790–792 (2021).
doi: 10.1038/s41591-021-01316-7
Petter, E. et al. Initial real world evidence for lower viral load of individuals who have been vaccinated by BNT162b2. Preprint at https://www.medrxiv.org/content/10.1101/2021.02.08.21251329v1 (2021).
Milman, O. et al. Community-level evidence for SARS-CoV-2 vaccine protection of unvaccinated individuals. Nat. Med. 27, 1367–1369 (2021).
doi: 10.1038/s41591-021-01407-5
Gazit, S. et al. BNT162b2 mRNA vaccine effectiveness given confirmed exposure; analysis of household members of COVID-19 patients. Preprint at https://www.medrxiv.org/content/10.1101/2021.06.29.21259579v1 (2021).
Rossman, H. et al. COVID-19 dynamics after a national immunization program in Israel. Nat. Med. 27, 1055–1061 (2021).
doi: 10.1038/s41591-021-01337-2
Our World in Data. https://ourworldindata.org/
Lopez Bernal, J. et al. Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant. N. Engl. J. Med. 385, 585–594 (2021).
doi: 10.1056/NEJMoa2108891
Mizrahi, B. et al. Correlation of SARS-CoV-2 breakthrough infections to time-from-vaccine; preliminary study. Preprint at https://www.medrxiv.org/content/10.1101/2021.07.29.21261317v1 (2021).
Goldberg, Y. et al. Waning immunity of the BNT162b2 vaccine: a nationwide study from Israel. Preprint at https://www.medrxiv.org/content/10.1101/2021.08.24.21262423v1 (2021).
Rosenberg, E. S. New COVID-19 cases and hospitalizations among adults, by vaccination status—New York, May 3–July 25, 2021. MMWR Morb. Mortal. Wkly. Rep. 70, 1306–1311 (2021).
Chia, P. Y. et al. Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine-breakthrough infections: a multi-center cohort study. Preprint at https://www.medrxiv.org/content/10.1101/2021.07.28.21261295v1 (2021).
Kissler, S. M. et al. Viral dynamics of SARS-CoV-2 variants in vaccinated and unvaccinated individuals. Preprint at https://www.medrxiv.org/content/10.1101/2021.02.16.21251535v3 (2021).
Bar-On, Y. M. et al. Protection of BNT162b2 vaccine booster against Covid-19 in Israel. N. Engl. J. Med. 385, 1393–1400 (2021).
doi: 10.1056/NEJMoa2114255
Corbett, K. S., Gagne, M., Wagner, D. & O’Connell, S. Protection against SARS-CoV-2 Beta variant in mRNA-1273 boosted nonhuman primates. Preprint at https://www.biorxiv.org/content/10.1101/2021.08.11.456015v1 (2021).
Levine-Tiefenbrun, M. et al. Association of COVID-19 RT–qPCR test false-negative rate with patient age, sex and time since diagnosis. Preprint at https://www.medrxiv.org/content/10.1101/2020.10.30.20222935v2 (2020).
Xin, H. et al. The incubation period distribution of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. Clin. Infect. Dis. https://doi.org/10.1093/cid/ciab501 (2021).
Fajnzylber, J. et al. SARS-CoV-2 viral load is associated with increased disease severity and mortality. Nat. Commun. 11, 5493 (2020).
doi: 10.1038/s41467-020-19057-5